NGENF
Price:
$2.17
Market Cap:
$218.66M
NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. Its lead product candidate is NVG-291 that is in phase 1 clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. The company has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is based in Vancouver, Canada.[Read more]
Industry
Biotechnology
IPO Date
2019-04-03
Stock Exchange
PNK
Ticker
NGENF
According to NervGen Pharma Corp.’s latest financial reports and current stock price. The company's current Current Ratio is 1.66. This represents a change of -0.81% compared to the average of 1.67 of the last 4 quarters.
The mean historical Current Ratio of NervGen Pharma Corp. over the last ten years is 5.70. The current 1.66 Current Ratio has changed 2.81% with respect to the historical average. Over the past ten years (40 quarters), NGENF's Current Ratio was at its highest in in the September 2020 quarter at 30.19. The Current Ratio was at its lowest in in the March 2018 quarter at 0.
Average
5.70
Median
5.68
Minimum
0
Maximum
16.16
Discovering the peaks and valleys of NervGen Pharma Corp. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = Infinity%
Maximum Annual Current Ratio = 16.16
Minimum Annual Increase = -85.98%
Minimum Annual Current Ratio = 0
Year | Current Ratio | Change |
---|---|---|
2023 | 0.83 | -63.51% |
2022 | 2.27 | -85.98% |
2021 | 16.16 | 96.73% |
2020 | 8.21 | 21.31% |
2019 | 6.77 | 19.21% |
2018 | 5.68 | Infinity% |
The current Current Ratio of NervGen Pharma Corp. (NGENF) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
6.42
5-year avg
6.85
10-year avg
5.70
NervGen Pharma Corp.’s Current Ratio is
Company | Current Ratio | Market cap |
---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like NervGen Pharma Corp. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like NervGen Pharma Corp. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is NervGen Pharma Corp.'s Current Ratio?
How is the Current Ratio calculated for NervGen Pharma Corp. (NGENF)?
What is the highest Current Ratio for NervGen Pharma Corp. (NGENF)?
What is the 3-year average Current Ratio for NervGen Pharma Corp. (NGENF)?
What is the 5-year average Current Ratio for NervGen Pharma Corp. (NGENF)?
How does the current Current Ratio for NervGen Pharma Corp. (NGENF) compare to its historical average?